The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The…
Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including the blockbuster tumor necrosis factor-alpha (TNF…
Friedreich’s ataxia (FA) is a progressive, autosomal recessive, neurodegenerative disease characterized by slowly advancing ataxia (loss of bodily control). No treatments are currently approved…
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…
Market Outlook U.S. gastroenterologists generally follow a step-up approach when treating Crohn’s disease patients that begins with safe, albeit often less efficacious, therapies (e.g.,…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and…
Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and…
MARKET OUTLOOK The moderate to severe AD market is at the beginning of a revolution with the recent approval of the first targeted AD biologic, Sanofi/Regeneron’s Dupixent, and a promising…
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care…
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care…
Patients with osteoporosis are at increased risk of fractures owing to the loss of bone strength, yet diagnosis and drug-treatment rates for this disease are relatively low. The low treatment rates…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
